Meeting
2020 ASCO Virtual Scientific Program
A phase III trial of capivasertib and paclitaxel in first-line treatment of patients with metastatic triple-negative breast cancer (CAPItello290).
Authors
Peter Schmid
Barts Cancer Institute, Centre for Experimental Cancer Medicine, London, United Kingdom
Peter Schmid , Javier Cortes , Mark E. Robson , Hiroji Iwata , Roberto Hegg , Marina Nechaeva , Binghe Xu , Sunil Verma , Vincent Haddad , Esteban Rodrigo Imedio , Gaia Schiavon , Andrew Foxley , Yeon Hee Park
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Triple-Negative
Clinical Trial Registration Number
NCT03997123
Citation
J Clin Oncol 38: 2020 (suppl; abstr TPS1109)
DOI
10.1200/JCO.2020.38.15_suppl.TPS1109
Abstract #
TPS1109
Poster Bd #
194
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
CONTESSA TRIO: A multinational, multicenter, phase (P) II study of tesetaxel (T) plus three different PD-(L)1 inhibitors in patients (Pts) with metastatic triple-negative breast cancer (TNBC) and tesetaxel monotherapy in elderly pts with HER2-metastatic breast cancer (MBC).
First Author: Sara M. Tolaney
First Author: Ana Oaknin
Poster
2019 ASCO Annual Meeting
Phase II COLET study: Atezolizumab (A) + cobimetinib (C) + paclitaxel (P)/nab-paclitaxel (nP) as first-line (1L) treatment (tx) for patients (pts) with locally advanced or metastatic triple-negative breast cancer (mTNBC).
First Author: Adam Brufsky
Poster
2018 ASCO Annual Meeting
IMpassion132: A double-blind randomized phase 3 trial evaluating chemotherapy (CT) ± atezolizumab (atezo) for early progressing locally advanced/metastatic triple-negative breast cancer (mTNBC).
First Author: Rebecca Dent